Cargando…
Relapsed/Refractory Chronic Lymphocytic Leukemia Patients Treated with Fixed Duration Venetoclax-Rituximab: Assessment of Response with Ultrasound, and Relationship with Minimal Residual Disease
A fixed duration of venetoclax-rituximab (VenR) resulted in a significant benefit of both PFS and in the attainment of an undetectable minimal residual disease (uMRD) compared with bendamustine-rituximab in relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL) patients. The 2018 International...
Autores principales: | , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10003523/ https://www.ncbi.nlm.nih.gov/pubmed/36902559 http://dx.doi.org/10.3390/jcm12051772 |
_version_ | 1784904622352105472 |
---|---|
author | Benedetti, Edoardo Baratè, Claudia Mavilia, Fabrizio Bramanti, Emilia Morganti, Riccardo Guerri, Valentina Cervetti, Giulia Capochiani, Enrico Bertaggia, Ilaria Stella, Salvatore Massimo Traverso, Ginevra Bruno, Benedetto Galimberti, Sara |
author_facet | Benedetti, Edoardo Baratè, Claudia Mavilia, Fabrizio Bramanti, Emilia Morganti, Riccardo Guerri, Valentina Cervetti, Giulia Capochiani, Enrico Bertaggia, Ilaria Stella, Salvatore Massimo Traverso, Ginevra Bruno, Benedetto Galimberti, Sara |
author_sort | Benedetti, Edoardo |
collection | PubMed |
description | A fixed duration of venetoclax-rituximab (VenR) resulted in a significant benefit of both PFS and in the attainment of an undetectable minimal residual disease (uMRD) compared with bendamustine-rituximab in relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL) patients. The 2018 International Workshop on CLL guidelines, outside the context of clinical trials, suggested ultrasonography (US) as a possible imaging technique to evaluate visceral involvement, and palpation to evaluate superficial lymph nodes (SupLNs). In this real-life study we prospectively enrolled N = 22 patients. Patients were assessed by US, to determine nodal and splenic response in R/R CLL patients treated with a fixed duration VenR. We found an overall response rate, complete remission, partial remission, and stable disease, of 95.4%, 68%, 27.3%, and 4.5%, respectively. Responses were also correlated with risk categories. The time to response, and the time to clearance of the disease in the spleen, in abdominal LN (AbdLNs), and in SupLNs were discussed. Responses were independent from LN size. The correlation between response rate with MRD were also investigated. US allowed to detect a substantial CR rate correlated with uMRD. |
format | Online Article Text |
id | pubmed-10003523 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-100035232023-03-11 Relapsed/Refractory Chronic Lymphocytic Leukemia Patients Treated with Fixed Duration Venetoclax-Rituximab: Assessment of Response with Ultrasound, and Relationship with Minimal Residual Disease Benedetti, Edoardo Baratè, Claudia Mavilia, Fabrizio Bramanti, Emilia Morganti, Riccardo Guerri, Valentina Cervetti, Giulia Capochiani, Enrico Bertaggia, Ilaria Stella, Salvatore Massimo Traverso, Ginevra Bruno, Benedetto Galimberti, Sara J Clin Med Article A fixed duration of venetoclax-rituximab (VenR) resulted in a significant benefit of both PFS and in the attainment of an undetectable minimal residual disease (uMRD) compared with bendamustine-rituximab in relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL) patients. The 2018 International Workshop on CLL guidelines, outside the context of clinical trials, suggested ultrasonography (US) as a possible imaging technique to evaluate visceral involvement, and palpation to evaluate superficial lymph nodes (SupLNs). In this real-life study we prospectively enrolled N = 22 patients. Patients were assessed by US, to determine nodal and splenic response in R/R CLL patients treated with a fixed duration VenR. We found an overall response rate, complete remission, partial remission, and stable disease, of 95.4%, 68%, 27.3%, and 4.5%, respectively. Responses were also correlated with risk categories. The time to response, and the time to clearance of the disease in the spleen, in abdominal LN (AbdLNs), and in SupLNs were discussed. Responses were independent from LN size. The correlation between response rate with MRD were also investigated. US allowed to detect a substantial CR rate correlated with uMRD. MDPI 2023-02-23 /pmc/articles/PMC10003523/ /pubmed/36902559 http://dx.doi.org/10.3390/jcm12051772 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Benedetti, Edoardo Baratè, Claudia Mavilia, Fabrizio Bramanti, Emilia Morganti, Riccardo Guerri, Valentina Cervetti, Giulia Capochiani, Enrico Bertaggia, Ilaria Stella, Salvatore Massimo Traverso, Ginevra Bruno, Benedetto Galimberti, Sara Relapsed/Refractory Chronic Lymphocytic Leukemia Patients Treated with Fixed Duration Venetoclax-Rituximab: Assessment of Response with Ultrasound, and Relationship with Minimal Residual Disease |
title | Relapsed/Refractory Chronic Lymphocytic Leukemia Patients Treated with Fixed Duration Venetoclax-Rituximab: Assessment of Response with Ultrasound, and Relationship with Minimal Residual Disease |
title_full | Relapsed/Refractory Chronic Lymphocytic Leukemia Patients Treated with Fixed Duration Venetoclax-Rituximab: Assessment of Response with Ultrasound, and Relationship with Minimal Residual Disease |
title_fullStr | Relapsed/Refractory Chronic Lymphocytic Leukemia Patients Treated with Fixed Duration Venetoclax-Rituximab: Assessment of Response with Ultrasound, and Relationship with Minimal Residual Disease |
title_full_unstemmed | Relapsed/Refractory Chronic Lymphocytic Leukemia Patients Treated with Fixed Duration Venetoclax-Rituximab: Assessment of Response with Ultrasound, and Relationship with Minimal Residual Disease |
title_short | Relapsed/Refractory Chronic Lymphocytic Leukemia Patients Treated with Fixed Duration Venetoclax-Rituximab: Assessment of Response with Ultrasound, and Relationship with Minimal Residual Disease |
title_sort | relapsed/refractory chronic lymphocytic leukemia patients treated with fixed duration venetoclax-rituximab: assessment of response with ultrasound, and relationship with minimal residual disease |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10003523/ https://www.ncbi.nlm.nih.gov/pubmed/36902559 http://dx.doi.org/10.3390/jcm12051772 |
work_keys_str_mv | AT benedettiedoardo relapsedrefractorychroniclymphocyticleukemiapatientstreatedwithfixeddurationvenetoclaxrituximabassessmentofresponsewithultrasoundandrelationshipwithminimalresidualdisease AT barateclaudia relapsedrefractorychroniclymphocyticleukemiapatientstreatedwithfixeddurationvenetoclaxrituximabassessmentofresponsewithultrasoundandrelationshipwithminimalresidualdisease AT maviliafabrizio relapsedrefractorychroniclymphocyticleukemiapatientstreatedwithfixeddurationvenetoclaxrituximabassessmentofresponsewithultrasoundandrelationshipwithminimalresidualdisease AT bramantiemilia relapsedrefractorychroniclymphocyticleukemiapatientstreatedwithfixeddurationvenetoclaxrituximabassessmentofresponsewithultrasoundandrelationshipwithminimalresidualdisease AT morgantiriccardo relapsedrefractorychroniclymphocyticleukemiapatientstreatedwithfixeddurationvenetoclaxrituximabassessmentofresponsewithultrasoundandrelationshipwithminimalresidualdisease AT guerrivalentina relapsedrefractorychroniclymphocyticleukemiapatientstreatedwithfixeddurationvenetoclaxrituximabassessmentofresponsewithultrasoundandrelationshipwithminimalresidualdisease AT cervettigiulia relapsedrefractorychroniclymphocyticleukemiapatientstreatedwithfixeddurationvenetoclaxrituximabassessmentofresponsewithultrasoundandrelationshipwithminimalresidualdisease AT capochianienrico relapsedrefractorychroniclymphocyticleukemiapatientstreatedwithfixeddurationvenetoclaxrituximabassessmentofresponsewithultrasoundandrelationshipwithminimalresidualdisease AT bertaggiailaria relapsedrefractorychroniclymphocyticleukemiapatientstreatedwithfixeddurationvenetoclaxrituximabassessmentofresponsewithultrasoundandrelationshipwithminimalresidualdisease AT stellasalvatoremassimo relapsedrefractorychroniclymphocyticleukemiapatientstreatedwithfixeddurationvenetoclaxrituximabassessmentofresponsewithultrasoundandrelationshipwithminimalresidualdisease AT traversoginevra relapsedrefractorychroniclymphocyticleukemiapatientstreatedwithfixeddurationvenetoclaxrituximabassessmentofresponsewithultrasoundandrelationshipwithminimalresidualdisease AT brunobenedetto relapsedrefractorychroniclymphocyticleukemiapatientstreatedwithfixeddurationvenetoclaxrituximabassessmentofresponsewithultrasoundandrelationshipwithminimalresidualdisease AT galimbertisara relapsedrefractorychroniclymphocyticleukemiapatientstreatedwithfixeddurationvenetoclaxrituximabassessmentofresponsewithultrasoundandrelationshipwithminimalresidualdisease |